Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

Kolek, Vı́tězslav; Losse, Stanislav; Kultan, Juraj; Jakubec, Petr; Zatloukal, Jaromír; Sova, Milan; Szkorupa, Marek; Neoral, C; Škarda, J; Tichý, Tomáš; Kolář, Zdeněk

doi:10.1080/03007995.2018.1490254

Cited by 7 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with NSCLC are at substantial risk for recurrence and death even after complete surgical resection [ 9 ]. The role of adjuvant chemotherapy for patients with resected stage IB disease is controversial [ 2 ]. However, in general chemotherapy is offered to medically appropriate patients with stage IB disease whose tumors display one or more high-risk features, including lymphovascular invasion, poor differentiation, high standardized uptake value (SUV) on positron emission tomography (PET; variably defined as SUV 10 or more).…”

Section: Discussionmentioning

confidence: 99%

“…In our patient, adjuvant therapy with cisplatin and vinorelbine was preferred due to the presence of a poorly differentiated tumor. Adjuvant chemotherapy in stage IB disease with tumor size >4 cm may also improve survival [ 2 ]. The primary goal of adjuvant therapy is to eradicate micrometastases, decreasing the rate of distant metastases and, thereby, increasing survival following resection [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

“…Adjuvant chemotherapy in stage IB disease with tumor size >4 cm may also improve survival [ 2 ]. The primary goal of adjuvant therapy is to eradicate micrometastases, decreasing the rate of distant metastases and, thereby, increasing survival following resection [ 2 ]. In patients with stages IIA, IIB, and IIIA after complete resection, adjuvant cisplatin-based chemotherapy has become a standard of care [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

“…The primary goal of adjuvant therapy is to eradicate micrometastases, decreasing the rate of distant metastases and, thereby, increasing survival following resection [ 2 ]. In patients with stages IIA, IIB, and IIIA after complete resection, adjuvant cisplatin-based chemotherapy has become a standard of care [ 2 ]. Adjuvant cisplatin-based doublet therapy, preferably with vinorelbine is recommended currently and has been documented to show the longest survival [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

“…Lung cancer is still the leading cause of cancer-related deaths, accounting for 1.4 million deaths worldwide [ 1 ] and approximately 160,000 deaths in the United States every year [ 1 ] with increasing incidence worldwide [ 2 ]. Giant cell carcinoma of the lung (GCCL) is a rare variant of non-small cell lung carcinoma (NSCLC), accounting for 0.1–0.4% of all lung cancers [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Habib

Leifer

Azam

et al. 2018

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Giant Cell Carcinoma of the lung, a subtype of Sarcomatoid lung cancer is a poorly differentiated Non-Small-Cell Lung Cancer. GCCL has exceptionally aggressive characteristics, and its prognosis is much poorer than any other NSCLCs. Herein, we present a rare case of Giant Cell Carcinoma of lung treated successfully with surgical resection and adjuvant vinorelbine and cisplatin.A 48-year-old African American man with a history of smoking and chronic obstructive pulmonary disease was admitted to the hospital for chief complaints of shortness of breath. He was found to have a 3.5 cm × 3.3 cm x 2.8 cm cavitary right upper lobe mass which turned out to be poorly differentiated Giant Cell Carcinoma with extensive necrosis and deemed similar to stage 1b non-small cell lung cancer. He was successfully treated with right upper lobectomy and adjuvant chemotherapy with vinorelbine and cisplatin. He was followed for seven years with no evidence of recurrent disease.Giant Cell Carcinoma's existing literature is limited, and hence our case is reportable. Our case is unique because of the better outcome which we believe might be the result of early detection and treatment with surgical resection along with adjuvant chemotherapy. More studies are needed to deeply understand the need for adjuvant chemotherapy in stage 1 b GCCL, and proper guidelines are required for the indications of adjuvant chemotherapy in Stage 1b GCCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Habib

Leifer

Azam

et al. 2018

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

show abstract

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer

Melosky,

Vincent,

McGuire

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Cure of cancer is a sensitive and multidimensional concept that is challenging to define, difficult to assert at the individual patient level, and often surrounded by controversy. The notion of cure in non‐small cell lung cancer (NSCLC) has changed and continues to evolve with improvements in diagnosis and treatment. Targeted and immune therapies have recently entered the treatment landscape of stage I–III NSCLC. While some initial pivotal trials of such agents failed to improve survival, recently approved epidermal growth factor receptor (EGFR) inhibitors (in EGFR‐mutated NSCLC) and immune checkpoint inhibitors have shown delays in disease recurrence or progression and unprecedented survival gains compared to previous standards of care. Additional data is now emerging supporting the benefit of treatment strategies based on alternation‐matched targeting (anaplastic lymphoma kinase [ALK] inhibition in ALK‐altered disease) and immune checkpoint inhibition in stage I–III NSCLC. Similar to previous developments in the treatment of early and locally advanced NSCLC, it is expected that statistically significant and clinically meaningful trial‐level benefits will translate into real‐world benefits, including improvements in cure measures. Parallel advances in molecular testing (e.g., circulating tumor DNA analyses) are also allowing for a deeper and more comprehensive characterization of disease status and treatment response. Given the impact that curative‐intent treatments have on survival, it is critical that various stakeholders, including clinicians and patients, are aware of new opportunities to pursue cure in stage I–III NSCLC.

show abstract

Giant cell carcinoma of the lung presenting as an isolated cyst containing air

Wang¹,

Liu²,

Qian³

et al. 2019

Medicine

View full text Add to dashboard Cite

Introduction: Pulmonary sarcomatoid carcinomas (PSCs) are rare tumors within the sarcomatoid carcinoma group. Giant cell carcinoma of the lung (GCCL) is a rare type of PSCs that consists entirely of highly pleomorphic tumor giant cells; the prognosis is poor. Patient concerns: A patient presented with a single cyst and was diagnosed with GCCL. The patient was a 59-year-old male who was admitted to the hospital with a cough. A chest computerized tomography (CT) scan showed a single, thin-walled cyst containing air in the left upper lobe of the lung. Bronchoscopy revealed chronic bronchitis. The initial diagnosis was pulmonary infection and the patient was treated with antibiotics. The cyst wall increased in thickness, and the cyst eventually formed a cavity. Diagnosis: Surgery was performed, and a diagnosis of GCCL was established. The stage was pT 1b N 1 M 0 (equal to stage IIB). Interventions: The patient underwent video-assisted thoracoscopic surgery and 4 cycles of adjuvant chemotherapy consisting of cisplatin and docetaxel. After 9 months, the patient occurred mediastinal lymph node metastasis, and received radiotherapy (60Gy/30F). Outcomes: His prognosis was good without progression (complete response) based on serial CT scans over 9 months of follow-up evaluations, then the patient occurred mediastinal lymph node metastasis. The patient lived during 30 months of follow-up, after which he was lost to follow-up. Conclusion: A solitary pulmonary parenchymal cystic lesion usually suggests an infectious disease or congenital abnormality; however, a cystic lesion is occasionally encountered in GCCL.

show abstract

Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

Abstract: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.

Cited by 7 publications

References 32 publications

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer

Giant cell carcinoma of the lung presenting as an isolated cyst containing air

Contact Info

Product

Resources

About